Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

Creator(s)

George S. Laszlo
Todd A. Alonzo
Chelsea J. Gudgeon
Kimberly H. Harrington
Alex Kentsis
Robert B. Gerbing
Yi-Cheng Wang
Rhonda E. Ries
Susana C. Raimondi
Betsy A. Hirsch
A S. Gamis, Children's Mercy HospitalFollow
Soheil Meshinchi
Roland B. Walter

Document Type

Article

Publication Date

11-30-2016

Identifier

PMCID: PMC5129595 DOI: 10.1186/s13045-016-0364-0

Journal Title

J Hematol Oncol

Volume

9

Issue

1

First Page

133

Last Page

133

MeSH Keywords

Aminoglycosides/therapeutic use; Antibodies, Monoclonal, Humanized/therapeutic use; Gene Expression Regulation, Leukemic/drug effects; Leukemia, Myeloid/drug therapy

Keywords

AML; children; MEF2C

Comments

Erratum for

High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.[J Hematol Oncol. 2015; PMID 27687643]

Grant support

• U10 CA180899/CA/NCI NIH HHS/United States

Recommended Citation

Laszlo GS, Alonzo TA, Gudgeon CJ, et al. Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. J Hematol Oncol. 2016;9(1):133. Published 2016 Nov 30. doi:10.1186/s13045-016-0364-0